Home > Financial Ratios > CORONA REMEDIES

CORONA REMEDIES
Core EBITDA Growth

    Back to All Ratios
CORONA REMEDIES is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
COMMUNITY POLL
for CORONA REMEDIES
Please provide your vote to see the results

CORONA REMEDIES Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023
   Core EBITDA Growth(%) 23.6652.5619.37-

What is the latest Core EBITDA Growth ratio of CORONA REMEDIES ?

The latest Core EBITDA Growth ratio of CORONA REMEDIES is 23.66 based on Mar2026 Consolidated results.
Year Core EBITDA Growth
Mar202623.66
Mar202552.56
Mar202419.37
Mar2023-

How is Core EBITDA Growth of CORONA REMEDIES Trending?

Years Core EBITDA Growth % Change
Mar2026 23.66
-54.98
Mar2025 52.56
171.35
Mar2024 19.37
0
Mar2023 0 -

Other Financial Ratios of CORONA REMEDIES


Compare Core EBITDA Growth ratio of peers of CORONA REMEDIES

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
CORONA REMEDIES ₹12,388.4 Cr -0.6% -3% NA Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹421,539.0 Cr -1.4% -6.6% 7.3% Stock Analytics
DIVIS LABORATORIES ₹247,576.0 Cr 1.2% -2.6% 60% Stock Analytics
TORRENT PHARMACEUTICALS ₹177,251.0 Cr -2% -6.1% 33% Stock Analytics
CIPLA ₹105,290.0 Cr -2.3% -5.8% -13.9% Stock Analytics
DR REDDYS LABORATORIES ₹99,752.6 Cr -1.1% 3.8% -5.5% Stock Analytics


CORONA REMEDIES Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
CORONA REMEDIES

-0.6%

-3%

NA
SENSEX

0.8%

-4.8%

-10.5%


You may also like the below Video Courses